Loading…
Lexicon Pharmaceuticals, Inc. is projected to rise to $3.22 by 2027, a +39% move from its current price of $2.31. LXRX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $2.25 | $2.31 | $2.38 | +0.11% |
| Aug 3 | $2.22 | $2.32 | $2.41 | +0.23% |
| Aug 4 | $2.20 | $2.32 | $2.44 | +0.34% |
| Aug 5 | $2.19 | $2.32 | $2.46 | +0.46% |
| Aug 6 | $2.17 | $2.32 | $2.48 | +0.57% |
| Aug 7 | $2.16 | $2.33 | $2.50 | +0.68% |
| Aug 8 | $2.15 | $2.33 | $2.52 | +0.80% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.15 | $2.33 | $2.52 | +0.80% |
| Week 2 | $2.10 | $2.35 | $2.62 | +1.60% |
| Week 3 | $2.07 | $2.37 | $2.71 | +2.41% |
| Week 4 | $2.04 | $2.38 | $2.79 | +3.23% |
| Week 5 | $2.02 | $2.40 | $2.86 | +4.06% |
| Week 6 | $2.00 | $2.42 | $2.94 | +4.89% |
| Week 7 | $1.98 | $2.44 | $3.00 | +5.72% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Lexicon Pharmaceuticals, Inc., LXRX, is a Healthcare biopharmaceutical company focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease.
The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors.
Lexicon has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
LXRX is currently priced at $2.34 with a market cap of $1.04B, ranking 2552.
The price is trading near the SMA50 of $2.01 and above the SMA200 of $1.57, signaling a near-term upward bias.
The 30-day range is $1.79 to $3.06, and RSI14 is 60.
The long-term outlook shows rising averages, with 2026 avg $2.34, 2027 avg $3.33, 2030 avg $6.93, 2040 avg $24.71, and 2050 avg $51.07, with bullish sentiment in the later years.
A major floor 34.6% below — a decisive break under it would weaken the trend.
The nearest floor, 13.0% below — buyers have tended to step in here.
The nearest ceiling, 14.3% above — a clean break opens room to run.
A major ceiling 27.7% above — clearing it would confirm fresh momentum.
Key LXRX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of LXRX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.31 | Buy | $2.31 | Sell |
| MA 10 | $2.31 | Buy | $2.30 | Buy |
| MA 20 | $2.28 | Buy | $2.28 | Buy |
| MA 50 | $2.18 | Buy | $2.18 | Buy |
| MA 100 | $1.97 | Buy | $2.00 | Buy |
| MA 200 | $1.67 | Buy | $1.75 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 53.18 | Neutral |
| Stoch RSI (14) | 51.28 | Neutral |
| CCI (20) | 31.75 | Neutral |
| Williams %R (14) | -29.63 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | 5.00 | Buy |
| Bollinger %B (20,2) | 0.60 | Neutral |
| Stochastic %K (14) | 70.37 | Neutral |
| TRIX (15) | 0.27 | Buy |
| Awesome (5,34) | 0.06 | Buy |
| Ultimate (7,14,28) | 58.64 | Neutral |
| Momentum (10) | -0.08 | Sell |
| Aroon Osc (25) | -40.00 | Sell |
| Hull MA (9) | 2.33 | Sell |
| ADX (14) | 11.26 | Neutral |
| ATR (14) | 0.06 | Info |
The 30-day technical picture leans bullish. RSI14 is 60, and the price sits above the 50-day moving average of $2.01, above the 200-day moving average of $1.57.
Support is at $1.85 and resistance at $2.64, with a 30-day range of $1.79 to $3.06.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.14 | $2.31 | $3.26 | 0% | Neutral | |
| $2.55 | $3.22 | $4.31 | +39% | Bullish | |
| $3.48 | $4.53 | $6.32 | +96% | Bullish | |
| $4.17 | $5.57 | $8.02 | +141% | Bullish | |
| $4.87 | $6.66 | $9.84 | +188% | Bullish | |
| $5.12 | $7.15 | $10.81 | +210% | Bullish | |
| $5.29 | $7.52 | $11.61 | +226% | Bullish | |
| $6.68 | $9.69 | $15.22 | +319% | Bullish | |
| $7.97 | $11.75 | $18.78 | +409% | Bullish | |
| $8.99 | $13.47 | $21.86 | +483% | Bullish | |
| $13.59 | $21.95 | $38.05 | +850% | Bullish | |
| $25.83 | $47.51 | $90.54 | +19.6x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.14 | $2.31 | $2.80 | +0.00% |
| September 2026 | $2.08 | $2.46 | $3.01 | +6.55% |
| October 2026 | $2.14 | $2.56 | $3.17 | +4.09% |
| November 2026 | $2.12 | $2.54 | $3.17 | -0.76% |
| December 2026 | $2.14 | $2.59 | $3.26 | +1.85% |
Click any year to see its month-by-month LXRX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, LXRX is projected to trade between $1.14 and $3.26, averaging $2.31 — a potential gain of 0% from today's $2.31. A consolidation phase looks the most probable path here.
Lexicon Pharmaceuticals, Inc.'s 2027 outlook centres on $3.22, within a $2.55 to $4.31 range. That is up +39% on the projected 2026 average. That marks a +39% change versus current levels. Momentum favours further upside here.
By 2028, LXRX could reach as high as $6.32, with a base case around $4.53 and support toward $3.48 — roughly +96% from $2.31. Buyers look set to stay in control over this stretch.
Expect LXRX to range from $4.17 to $8.02 through 2029. The $5.57 average target implies a +141% move from current prices. That is up +23% on the projected 2028 average. Momentum favours further upside here.
The LXRX price prediction for 2030 points to an average of $6.66 (low $4.87, high $9.84) — a potential gain of +188% on today's $2.31. Buyers look set to stay in control over this stretch.
In 2031, LXRX is projected to trade between $5.12 and $10.81, averaging $7.15 — a potential gain of +210% from today's $2.31. That is up +7% on the projected 2030 average. Momentum favours further upside here.
Lexicon Pharmaceuticals, Inc.'s 2032 outlook centres on $7.52, within a $5.29 to $11.61 range. That is up +5% on the projected 2031 average. That marks a +226% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, LXRX could reach as high as $15.22, with a base case around $9.69 and support toward $6.68 — roughly +319% from $2.31. Momentum favours further upside here.
Expect LXRX to range from $7.97 to $18.78 through 2034. The $11.75 average target implies a +409% move from current prices. That is up +21% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The LXRX price prediction for 2035 points to an average of $13.47 (low $8.99, high $21.86) — a potential gain of +483% on today's $2.31. Momentum favours further upside here.
In 2040, LXRX is projected to trade between $13.59 and $38.05, averaging $21.95 — a potential gain of +850% from today's $2.31. That is up +63% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Lexicon Pharmaceuticals, Inc.'s 2050 outlook centres on $47.51, within a $25.83 to $90.54 range. That is up +116% on the projected 2040 average. That marks a +19.6x change versus current levels. Momentum favours further upside here.
Investing $1,000 in LXRX today (≈ 432.900433 LXRX) could be worth
$20,565.57
+$19,565.57 (+1957%) by 2050 · US Dollar
Based on the average projected LXRX price of $47.51 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in LXRXwould be worth at today's price.
$1,000 invested in LXRX on Jul 31, 2025 (≈ 934.579393 LXRX) would be worth
$2,158.88
+$1,158.88 (+115.9%) today · 2.16× · US Dollar
Based on a LXRX entry price of $1.07 vs. today's $2.31.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.29 | $1,008.73 | +0.9% |
| 1 month ago | $2.34 | $987.18 | -1.3% |
| 3 months ago | $1.63 | $1,417.18 | +41.7% |
| 6 months ago | $1.25 | $1,848 | +84.8% |
| 1 year ago | $1.07 | $2,158.88 | +115.9% |
| All time (5.0y) ago | $3.65 | $632.88 | -36.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our LXRX forecast.
Our base-case forecast reaches $4.60 around 2029.
Implied market cap at $4.60: $2.04B
The multi-year forecast shows upside potential with a neutral stance in 2026: min $1.14, avg $2.34, max $3.67, ROI 0, sentiment NEUTRAL.
In 2030 the average is $6.93 with a min of $4.69 and a max of $11.08, ROI 196, sentiment BULLISH.
In 2040 the average rises to $24.71 (min $12.97, max $48.14), ROI 955.8, sentiment BULLISH.
In 2050 the average is $51.07 (min $22.98, max $111.58), ROI 2082.7, sentiment BULLISH. These figures are estimates, not guarantees.
Tap a question to reveal the answer.
2030 avg $6.93, min $4.69, max $11.08, ROI 196%, sentiment BULLISH.
The 2026 forecast shows min $1.14, avg $2.34, max $3.67 with ROI 0 and neutral sentiment. From 2027 onward, forecasts are bullish with rising averages and ROIs (e.g., 2027 avg $3.33, ROI 42.2%; 2028 avg $5.15, ROI 120.2%).
Yes—the 2026 max is $3.67 and 2027 avg is $3.33, indicating potential to surpass $3 in 2026-2027.
2040 avg $24.71, min $12.97, max $48.14, ROI 955.8%, sentiment BULLISH.
2050 avg $51.07, min $22.98, max $111.58, ROI 2082.7%, sentiment BULLISH.
Lexicon Pharmaceuticals, Inc. Community Discussion
0Share your Lexicon Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.